HETRAZAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hetrazan, and what generic alternatives are available?
Hetrazan is a drug marketed by Lederle and is included in one NDA.
The generic ingredient in HETRAZAN is diethylcarbamazine citrate. There are five drug master file entries for this compound. Additional details are available on the diethylcarbamazine citrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HETRAZAN?
- What are the global sales for HETRAZAN?
- What is Average Wholesale Price for HETRAZAN?
Summary for HETRAZAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 1 |
| Patent Applications: | 394 |
| DailyMed Link: | HETRAZAN at DailyMed |
Recent Clinical Trials for HETRAZAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Case Western Reserve University | Phase 3 |
| Washington University School of Medicine | Phase 3 |
| Regional Hospital of Agboville, Southern Cote d'Ivoire | Phase 3 |
US Patents and Regulatory Information for HETRAZAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lederle | HETRAZAN | diethylcarbamazine citrate | TABLET;ORAL | 006459-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
